NA
FLGT icon

Navellier & Associates’s Fulgent Genetics FLGT Stock Holding History

Navellier & Associates’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-33,895
Closed -$3.41M – 306
2021
Q4 		$3.41M Buy
33,895
+3,814
+13% +$335K 0.5% 67
2021
Q3 		$2.71M Buy
30,081
+3,133
+12% +$285K 0.41% 76
2021
Q2 		$2.48M Buy
26,948
+4,380
+19% +$350K 0.37% 84
2021
Q1 		$2.18M Buy
22,568
+13,656
+153% +$1.41M 0.39% 87
2020
Q4 		$464K Buy
+8,912
New +$372K 0.08% 176

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Navellier & Associates's FLGT Position: Q1 2022 in Review

Navellier & Associates sold out of Fulgent Genetics (FLGT) in Q1 2022, closing a stake of 33,895 shares — an estimated $3.41M sold.

Navellier & Associates first reported a position in FLGT in Q4 2020 and held it in 5 quarters. The position peaked at $3.41M in Q4 2021. 275 funds tracked by Wall St. Rank hold FLGT as of Q1 2022.

  • Navellier & Associates reported no remaining Fulgent Genetics position as of Q1 2022 after selling out during the quarter.
  • Navellier & Associates sold 33,895 Fulgent Genetics shares in Q1 2022, an estimated $3.41M.
  • Navellier & Associates first reported a position in Fulgent Genetics in Q4 2020 and held it in 5 quarters.
  • Navellier & Associates's Fulgent Genetics position peaked at $3.41M in Q4 2021.
  • 275 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2022.

Based on Navellier & Associates's 13F filing for Q1 2022, filed 29 Apr 2022.